The Biggest Disruption Nobody Saw Coming
Weight loss drugs are disrupting more industries than AI. GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) reduce caloric intake by 20-30% for millions. When tens of millions eat 25% less food, ripple effects touch everything.
Who Loses
Food & beverage: Snack companies seeing declining volumes. Restaurants reporting smaller orders. Walmart's CEO noted Ozempic users buy less food.
Bariatric surgery: Surgery volumes plummeting. Why get surgery when a weekly injection works better?
Who Wins
Novo Nordisk & Eli Lilly: Printing money. Ozempic/Wegovy alone generated $18+ billion in 2025.
Fitness industry: People losing weight want to build muscle. Gym memberships booming among GLP-1 users.
Health insurers: If GLP-1s reduce obesity-related conditions, insurers save billions long-term.
Investment Takeaway
Long LLY and NVO. Short companies dependent on overconsumption. Watch second-order effects — from airline fuel savings to reduced healthcare costs. This isn't a trend. It's a transformation.
